The CRO market continues to exhibit stellar growth, largely attributable to increased demand for services in clinical trials between Phases II and IV, which account for approximately REDACTED of total CROrevenue. All segments, including preclinical and post-approval, continue to grow solidly as well. Outlook for the industry remains extremely positive; with the proliferation of therapies for orphan drugs and precision-based medicines, clinical trials are becoming increasingly complex and are driving demand for sophisticated outsourcing partners with expertise in combination products, risk-based monitoring, disease registries, real world evidence and medical affairs. Expanding service offerings and capabilities remain a predominant strategy among CROs.
CROs obtain the lions share of their revenue from actual clinical trials, which accounted for nearly REDACTED in CRO revenue last year. Discovery, preclinical and central lab services all represent strong areas of growth despite accounting for a smaller share of revenue.
The geographical distribution of clinical trials is slowly shifting from developed nations to emerging countries; rising costs of trials and difficulty in patient recruitment has led biopharma companies to shift toward regions such as Central and Eastern Europe, Asia-Pacific and Latin America for quicker patient recruitment and cost savings. The greater disease variation among developing countries also helps create more diverse population samples, particularly for rare disease studies.
Based on indication, the oncology segment is the largest and one of the most rapidly growing within the CRO space, with nearly REDACTED spent in 2016 on preclinical and clinical oncology trials. Pain management remains one of the faster growing and more lucrative disease areas, with new treatments for chronic and acute pain and rising investigational studies for Non-Steroidal Anti-Inflammatory Drug (NSAID) and analgesic molecules driving this segment.
The dominant players in the industry are Quintiles IMS, Covance, PAREXEL, Charles River Labs and ICON. Mergers and acquisitions by these and other larger companies in this space continue at an unprecedented pace; high valuations along with the increasing need to become complete service providers are driving this trend.
Key drivers impacting CRO market growth include globalization of clinical trials, development of new treatments such as personalized medicine, augmenting evolution of technology and greater penetration of CROs into the clinical trial process. The demand or biogenetics and particularly biosimilars will be a clear driver going forward.
Current pharma R&D spending is being driven by precision-based medicines and immunotherapies for smaller populations, genetic therapies for oncology and rare disease treatment and generally more demanding and complex protocols for drug development.
The clinical trial environment continues to be tied to exorbitant costs as complex therapies requiring larger and more diverse samples are extending the time required and geographies involved to conduct a typical study. In an effort to contain these costs and shorten development timelines, pharma and biopharma firms are increasingly outsourcing many services associated with the development of todays complex therapies to CROs."
The Global CRO market is identified in this report along with all major global CRO companies. The total CRO market is broken out globally and by geographic region. Additionally, all major therapeutic areas covered by CROs in the clinical trial process are detailed. The service areas provided by CROs are extensively covered as well. The phases of the clinical trial process and the role provided by CROs are detailed in this report as well.
This report provides detailed analysis of top CRO companies and their evolving role in the clinical trial process. Faced with rapid development of new therapies, Pharmaceutical companies are increasingly turning to CROs for their services. CROs expertise within specific therapeutic areas as well as their experience with new and adaptive study design protocols, can reduce costs and study duration. With typical clinical trials costing upwards of $2.5 billion and spanning over a decade from initial testing to Phase IV and post market approval, a thriving market exists to lower these costs and timelines. CROs are expected to continue to play an increasingly role in many facets of the clinical trial process. Oncology, neurology, cardiovascular, metabolism-diabetes, vaccines and other rapidly growing therapeutic areas that have a significant number of drugs in the clinical trial process are detailed in this report.
Strong demand for CRO services is leading to heightened market valuations and correspondingly a plethora of blockbuster Merger and Acquisition deals are taking place. M&A activity has led to a few powerful companies with expertise across many areas of the clinical trial process, although many niche players are still playing a critical role. These emerging trends and changing dynamics within the CRO industry are analyzed in detail in this report.
- 19 tables
- An overview of the global market for contract research organization (CRO) services
- Analyses of global market trends, with data from 2016, 2017, and projections of compound annual growth rates (CAGRs) through 2022
- Analyses of the CRO market by services, trial phases, and geographical region
- Coverage of all major therapeutic areas covered by CROs in the clinical trial process and the types of services they provide
- Examination of competitive landscape of the market, including mergers and acquisitions, and current pharma CRO contracts
- Company profiles of key market players, including Charles River Laboratories, Icon Plc, Parexel, Pharmaceutical Product Development and Quintiles"
Table of Contents
Chapter 1 Introduction
Global CRO Market Trends
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
BCC Custom Research
Related BCC Research Reports
Chapter 2 Summary and Highlights
Chapter 3 Overview-Clinical Trial Process and CRO Functional Services
Clinical Trial Process and Stages
Post-Marketing Surveillance and Phase IV Studies
FDA Regulation and Impact
The Declaration of Helsinki
Current Market Trends
Repurposing Existing Drugs for New Indications
Increased Competition through the Resurgence of the Generic Drug Market
Chapter 4 Global Market Overview
Global Clinical Trials Shifting toward Asia-Pacific
Chapter 5 Emerging Trends
Increasing Complexity of Clinical Trials
Small and Mid-sized Biopharma Innovation
Small Molecule Versus Biologics
Adaptive Trial Design
Real World Evidence
Chapter 6 Competitive Landscape
Functional Service Provider Relationships
Therapeutic Areas in Drug Development
Current Pharma-CRO Contracts
Largest Therapeutic Areas Rely on Key CRO Expertise
Chapter 7 Mergers and Acquisitions
Recent Merger and Acquisition Activity
LabCorp, Covance and Chiltern
INC Research/Inventiv Health
ICON and MAPI
Parexel and Pamplona
Chapter 8 Company Profiles
Top 10 CROs
CHARLES RIVER LABORATORIES
INC RESEARCH/INVENTIVE HEALTH
PHARMACEUTICAL PRODUCT DEVELOPMENT
PRA HEALTH SERVICES
List of Table
List of Tables
Summary Table : Global CRO Market Across the Clinical Trial Process, by Functional Service, Through 2022
Table 1 : Global CRO Market, by Therapeutic Area, Through 2022
Table 2 : Likelihood of Approval, by Major Disease Area/Phase
Table 3 : Clinical Phase Description
Table 4 : New Drug Approvals: New Drugs Entering the Market at an Increasing Pace Until Last Year, 20062017
Table 5 : Global CRO Market, by Functional Services, Through 2022
Table 6 : Increasing Complexity of Clinical Trials, by Design Characteristics in a Typical Clinical Study, 2002-2012
Table 7 : Small Molecule and Biologics FDA Drug Approvals, 20102016
Table 8 : Global CRO Market for FDA-Approved Small Molecule and Biologics Drugs, Through 2022
Table 9 : Global CRO Market, by Therapeutic Area, Through 2022
Table 10 : Key Players in Therapeutic Areas
Table 11 : Pharma and CRO Partnership Alliances
Table 12 : Surging CRO Deal Values, 20112017
Table 13 : Pharma M&A and Capital Raising Deal Values Increasing Value of Deals, 20102016
Table 14 : M&A Activity Among Pharma/CROs: Recent M&A Deals in Pharma Outsourcing Sector
Table 15 : Deal Types in CRO Sector: Improving Capital Markets Leading to More IPOs
Table 16 : Service Offerings, by Major CRO
Table 17 : Quintiles Explosive Growth via Acquisitions, Through 2016
Table 18 : Quintiles Key Financial and Synergistic Milestones During the Past Five Years
List of Chart
List of Figures
Summary Figure : Global CRO Market Across the Clinical Trial Process, by Functional Service, 20162022
Figure 1 : Clinical Pipeline, by Development Phase, 20072016
Figure 2 : Clinical Trial Outsourcing Share, by Functional Service, 2016
Figure 3 : Drug Approval Timeline
Figure 4 : Generic Drug Approvals and Filings in the U.S.,2015-2017
Figure 5 : Average Cost for an Approved Drug, 19702010
Figure 6 : Global CRO Market Size and Growth, 20152022
Figure 7 : Pharma R&D Spending Continues at a Steady Pace, 20062022
Figure 8 : Strong Prescription Drug Sales, 20142022
Figure 9 : CRO are Penetrating Further into R&D Budgets, 20122017
Figure 10 : Global CRO Functional Service Areas Market Share, by Type, 2016
Figure 11 : Global CRO Clinical Trial Market Share, by Phase, 2016
Figure 12 : Global CRO Competitor Market Share, by Company, 2017
Figure 13 : Leading CROs Preclinical CRO Market Share, by Company, 2017
Figure 14 : Leading CROs Clinical Market Share, by Company, 2017
Figure 15 : Therapeutic Clinical Pipeline Share, by Therapeutic Area, 2017
Figure 16 : Expanding Value of Outsourcing Deals Involving CROs, 20072017
Make an enquiry before buying this Report
Please fill the enquiry form below.